Zedoarondiol inhibits atherosclerosis by regulating monocyte migration and adhesion via CXCL12/CXCR4 pathway.
Adhesion
Atherosclerosis
Migration
Monocyte
Single-cell RNA sequencing
Zedoarondiol
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
26
04
2022
revised:
22
06
2022
accepted:
24
06
2022
pubmed:
1
7
2022
medline:
10
8
2022
entrez:
30
6
2022
Statut:
ppublish
Résumé
Atherosclerosis (AS) is an essential pathological changes of ischemic cardio-cerebrovascular disease, and monocyte migration and adhesion to endothelial cells are the critical pathological process in AS. Our previous studies demonstrated a beneficial effect of zedoarondiol in AS, but whether the mechanism is associated with monocyte migration and adhesion to endothelial cells remains unclear. In this study, we investigated whether the anti-atherosclerotic effects of zedoarondiol were associated with decreasing migration and adhesion of monocytes. The oil red O staining demonstrated that zedoarondiol ameliorated AS plaques in en face aorta and aortic root of apolipoprotein E gene knocked (apoE
Identifiants
pubmed: 35772647
pii: S1043-6618(22)00273-0
doi: 10.1016/j.phrs.2022.106328
pii:
doi:
Substances chimiques
CXCL12 protein, human
0
CXCR4 protein, human
0
Chemokine CXCL12
0
Lactones
0
Receptors, CXCR4
0
Sesquiterpenes
0
zedoarondiol
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106328Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.